Teva’s Neutropenia Drug Approved by FDA

by Kathy Jones on  August 31, 2012 at 7:58 PM Drug News
RSS Email Print This Page Comment bookmark
Font : A-A+

The US Food and Drug Administration has revealed that it has approved Teva Pharmaceutical Industries' neutropenia drug that will help increase the production of infection-fighting white blood cell among patients who are undergoing chemotherapy.
 Teva’s Neutropenia Drug Approved by FDA
Teva’s Neutropenia Drug Approved by FDA

With Amgen's patent for its biologic drug Neupogen expiring next year; the FDA has approved Teva's tbo-filgrastim, which is similar to Neupogen. However Teva will not be able to market its drug until November 2013 following a settlement of patent litigation with Amgen last year.

Stating that the drug may help patients recover faster from neutropenia, FDA's Richard Pazdur said, "Supportive care products, such as tbo-filgrastim, reduce or allow for more rapid recovery from side effects of cancer treatments."

Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity Leucopenia / Leukopenia Signature Drug Toxicity Neutropenia 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive

Loading...